Open AccessLymphoma immunophenotyping: “borderline” lymphomas
Author(s) -
MutPopescu Delia,
Lupu Anca,
Bumbea H.,
Vladareanu AnaMaria,
Barbu Doina,
Angelescu Silvana,
Olteanu Nicoleta,
Colita A.
Publication year - 2000
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2000.tb00118.x
Subject(s) - cd5 , immunophenotyping , mantle cell lymphoma , chronic lymphocytic leukemia , lymphoproliferative disorders , medicine , lymphoma , cd23 , pathology , leukemia , immunology , cancer research , antibody , antigen , immunoglobulin e
Immunophenotyping of B‐cell lymphoproliferative disorders is indispensable, especially in disorders with CD19(+) CD5(+) B lymphocytes, where we have to make the distinction between low grade neoplasia, such as chronic lymphocytic leukemia with CD23(+) malignant lymphocytes, and aggressive neoplasia such as mantle cell lymphoma with CD23(‐) malignant lymphocytes. We found some cases of CD19(+) CD5(+) lymphoproliferative disorders that do not meet all criteria for diagnosis of chronic lymphocytic leukemia or mantle cell lymphoma. For instance, we found cases with a low or no expression of CD23, asociated with absence of expression of FMC7 and surface immunoglobulins. These cases could be classified as “borderline” CD19(+) CD5(+) B cell lymphoproliferative disorders, with an intermediate neoplasic grade.